In neurodegenerative diseases like Alzheimer's disease (AD), tau is hyperphosphorylated and forms aggregates and neurofibrillary tangles in affected neurons. Autophagy is critical to clear the aggregates of disease-associated proteins and is often altered in patients and animal models of AD. Because mechanistic target of rapamycin (mTOR) negatively regulates autophagy and is hyperactive in the brains of patients with AD, mTOR is an attractive therapeutic target for AD. However, pharmacological strategies to increase autophagy by targeting mTOR inhibition cause various side effects. Therefore, autophagy activation mediated by non-mTOR pathways is a new option for autophagy-based AD therapy. Here, we report that pimozide activates autophagy to rescue tau pathology in an AD model. Pimozide increased autophagic flux through the activation of the AMPK-Unc-51 like autophagy activating kinase 1 (ULK1) axis, but not of mTOR, in neuronal cells, and this function was independent of dopamine D2 receptor inhibition. Pimozide reduced levels of abnormally phosphorylated tau aggregates in neuronal cells. Further, daily intraperitoneal (i.p.) treatment of pimozide led to a recovery from memory deficits of TauC3 mice expressing a caspasecleaved form of tau. In the brains of these mice, we found increased phosphorylation of AMPK1 and ULK1, and reduced levels of the soluble oligomers and NP40-insoluble aggregates of abnormally phosphorylated tau. Together, these results suggest that pimozide rescues memory impairments in TauC3 mice and reduces tau aggregates by increasing autophagic flux through the mTOR-independent AMPK-ULK1 axis.
Tau protein localized in the axonal region of neurons binds to and stabilizes microtubules (Schweers et al. 1994) . Tau protein is soluble and does not form insoluble aggregates in neurons under normal conditions. In Alzheimer's disease (AD) and other tauopathies, in contrast, tau protein is found in intracellular filaments with neuronal dysfunctions (Lasagna-Reeves et al. 2011) and, as the disease progresses, the number of tau tangles increases in disease-related regions, such as the hippocampus and cortex regions (Braak and Braak 1995) . In these neurons, pathologic tau proteins show multiple levels of oligomerization orders, such as detergent-soluble low molecular weight tau oligomers and detergent-insoluble tau with high molecular weight tau aggregates (Cowan et al. 2015) . In general, tau protein in these oligomers and aggregates is diversely and posttranslationally modified through phosphorylation, truncation, and other modifications (Citron 2010) . It is difficult to determine which of the various tau forms causes the disease, e.g., a modified monomeric form, soluble oligomeric forms, or insoluble aggregates of tau, but both oligomers and aggregates of the tau protein are pathological species and play an essential role in the pathogenesis of AD (Berger et al. 2007) .
Because AD animal models with decreased protein oligomers or aggregates show attenuated pathogenic phenotypes, such as a decreased number of tangles and enhanced memory (Frake et al. 2015) , there seems to be a linkage between tau aggregation and protein degradation/clearance machineries, especially autophagy. Autophagy is a selfdigestion process involving sequestration of cell structures or even organelles, and a unique property of autophagy is to degrade insoluble protein aggregates (Cuervo 2008) . Insoluble protein aggregates are frequently found in chronic neurodegenerative diseases, such as AD, Parkinson's disease, Huntington's disease (HD), and amyotrophic lateral sclerosis (Ciechanover and Brundin 2003; Baehrecke 2005) . In these diseases, the reduced activity of autophagy is accompanied by accumulation of the aggregation-prone protein species, especially tau oligomers and aggregates in tauopathies including AD. Rapamycin, an mechanistic target of rapamycin (mTOR) inhibitor that can induce macroautophagy, has been developed as a therapeutic agent for neurodegenerative diseases and significantly attenuates disease progress in animal models of AD, Parkinson's disease, HD, and other aggregation-mediated neurodegenerative diseases (Ravikumar et al. 2004; Caccamo et al. 2010; Nixon 2013) . However, inhibition of mTOR leads to many side effects, including immune deficiency and decrease in essential protein synthesis (Pallet and Legendre 2013) . Non-mTOR-mediated autophagy-inducible mechanisms are therefore needed and can support AD treatment.
Pimozide has been used for the treatment of schizophrenia since 1963 and is now used for the treatment of Tourette syndrome and resistant tics (Colvin and Tankanow 1985) . It is known to function as a dopamine D2 antagonist (Schwinn et al. 1976) . Recent studies show that pimozide induces autophagy independent of mTOR (Zhang et al. 2007 ) and decreases protein aggregation in a-1-antitrypsin-deficient C. elegans (Gosai et al. 2010) . However, molecular determinants responsible for the regulation of the mTORindependent autophagy by pimozide remain unknown. Our goal was to test the hypothesis that pimozide activated autophagy to reduce tau aggregates and mitigate AD pathology. In this paper, we identified pimozide as an important inducer of AMPK-mediated, but not mTORmediated, autophagy. We further found that pimozide decreased levels of tau oligomers and aggregates and rescued memory deficits in a novel aggregation-prone tau mouse model, TauC3 mice , through an increase in autophagy.
Materials and methods
Cell culture and DNA transfection HeLa (RRID:CVCL_0030) and SH-SY5Y (RRID:CVCL_0019) cells were cultured in Dulbecco's modified Eagle's medium (HyClone, South Logan, UT, USA) supplemented with 10% (v/v) fetal bovine serum (HyClone). Wild-type (WT) and AMPKa1/2 double knockout mouse embryo fibroblasts (MEFs) were kindly gifted from Dr. B. Viollet (Institute of Cochin, Universit e Paris Descartes, France). Cell lines were transfected using the PolyFect reagent (Qiagen, Valencia, CA, USA), whereas primary neurons were transfected using the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. GFP-tau, GFP-microtubule-associated protein light chain 3 (LC3), and mCherry-GFP-LC3 were described previously (Kim et al. 2015) .
Primary culture and dendritic spine density analysis Primary neurons were prepared as described previously (Kam et al. 2013) . Briefly, hippocampal neurons were cultured from embryonic day 16 C57BL/6 WT mice (Orient Bio Inc, Gyunggi-do, Korea) and incubated for 2 weeks in neurobasal media (GIBCO BRL, Carlsbad, CA, USA) containing B27 (Invitrogen). The neurons (DIV-15) were transfected with DsRed plasmid for 24 h and then treated with 5 lM synthetic oligomeric amyloid-beta (Ab) 42 alone or together with 1 lM pimozide or sulpiride for 12 h. Cultures were fixed in 4% paraformaldehyde for 10 min, images of the cells were acquired by fluorescence microscopy (Olympus, Tokyo, Japan) and the numbers of spines on the dendrites (numbers of spine within 10 lm of dendritic length) of randomly chosen neurons were counted by the experimenter blinded to the drug treatment (n = 21).
Preparation of oligomeric amyloid beta1-42
The dried synthetic Ab 1-42 peptide (Sigma-Aldrich, St. Louis, MO, USA) was first dissolved in dimethylsulfoxide at 2.2 mM, and then diluted in phosphate-buffered saline (PBS), to obtain a 250 lM stock solution. This solution was incubated at 4°C for at least 24 h and stored at À80°C until use. Before use, the solution was centrifuged at 12 000 g for 10 min and the supernatant was used as an oligomeric Ab 42 . The Ab 42 preparation was evaluated by neurotoxicity and western blot analysis using anti-Ab or Nu-1 antibody.
Western blot analysis
The cell and tissue lysates were prepared as described previously . In brief, cells were lysed with Tris-buffered saline extraction buffer (20 mM Tris-Cl pH 7.4, protease inhibitor cocktail with 0.5% NP-40). To detect 170 kDa tau oligomer, cells were lysed with oligomer extraction buffer (Tris-buffered saline buffer containing 2 mM N-ethylmaleimide), reassembly buffer [0.1 M 2-(Nmorpholino) ethanesulfonic acid pH 7.0, 1 mM EGTA and protease inhibitor cocktail] or radioimmunoprecipitation assay buffer (RIPA) buffer [50 mM Tris-Cl pH 8.0, 0.5% NP-40, 5 mM EDTA, 150 mM NaCl, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS)]. RIPA-insoluble tau aggregates were solubilized with 70% formic acid (FA). Samples were then solubilized in SDS-sampling buffer with or without b-mercaptoethanol to examine different tau species.
Antibodies
For western blotting, the following antibodies were used: HT7 antibody (RRID:AB_223454, MN1000; Thermo Scientific, Rockford, IL, USA); TauC3 antibody (RRID:AB_2536237, AHB0061; Invitrogen); ATG5 (RRID:AB_828587, NB110-53818), LC3 Filter trap assay for tau aggregates A filter trap assay was performed as previously described (Park et al. 2012) . In brief, cell lysates were filtered through a nitrocellulose membrane by using a 96-well vacuum dot blot apparatus (Bio-Rad Laboratories, Hercules, CA, USA) and the filters were subjected to western blotting.
Histology and immunohistochemistry
Mice were transcardially perfused with PBS, followed by perfusion fixation with 4% paraformaldehyde. Their brains were further cryoprotected in 30% sucrose in PBS. Immunohistochemistry was performed on 30-lm thick coronal free-floating cryosections. The sections were processed with an ABC Kit (Vector Laboratories, Burlingame, CA, USA) and were developed using 3,3-diaminobenzidine. The following primary antibodies were used for immunohistochemistry: TauC3 (1 : 50), PHF-1 (1 : 100), and MC-1 (1 : 10).
Animal care
We have generated TauC3 mice with the BALB/c background . Mice were raised under a 12 : 12 h light-dark cycle with free access to food and water ad libitum. All animal protocols were approved by the Seoul National University Standing Committee on Animals and performed in accordance with the US Public Health Services Guide for the Care and Use of Laboratory Animals.
Pimozide treatment of mouse model and behavior tests All mice experiments were performed in accordance with the ARRIVE guidelines (Kilkenny et al. 2010) , including blinding, appropriate controls, inclusion and exclusion criteria, reporting of all animals used, and so on. WT and TauC3 mice were assigned arbitrarily to two groups to inject PBS and pimozide, respectively. During the procedure, the experiments performed by two experimenters who were blind to the allocation of the animals. An experimenter labeled all animals before allocation. Tests were performed by investigators who were blinded to group allocation. Behavior tests were performed as previously described (Kam et al. 2013) . WT mice and age-matched TauC3 mice were treated with either PBS or 10 mg/kg/day pimozide by daily i.p. injection. Each mouse group was tested for different types of memory function, in a Y-maze, and on novel object recognition tasks. Examinations were performed at 1.3 and 2 months of age for 3 weeks. We initially assigned eight males and eight females per WT PBS and pimozide groups, and 10 males and 10 females per TauC3 PBS and pimozide groups. In the Y-maze test, the mice that did not enter the three arms for the first minute were excluded. In the novel object recognition test, we excluded animals that did not show interest in the object (less than 7 s of seek time) and those that did not equally recognize two identical objects but showed strong interest in only one object (> 60%) on the first day of the experiment. Therefore, the number of animals in each group was different (n = WT PBS, four males and six females; WT pimozide, five males and five females; TauC3 PBS, eight males and six females; TauC3 pimozide, eight males and five females). For Y-maze test, we noticed mean 10% difference in alteration between groups with standard deviation of approximately 7%. Therefore, we required a minimum of eight animals per group to detect such a difference at 95% confidence (a = 0.05) and 0.8 power. For novel recognition test, we noticed mean 9% difference in distinct parameters (spending time orienting toward the object, sniffing the object, or touching it with the nose) between groups with standard deviation of approximately 6%. Therefore, we required a minimum of seven animals per group (95% confidence, 0.8 power).
Y-maze: A triangular Y-shaped maze was made from black plastic, with arm size of 32.5 9 15 cm (length 9 height). Each mouse was placed at the end of one arm and allowed to move freely through the maze for 7 min. The percentage of spontaneous alterations was calculated as the ratio of the number of successful alternations to the number of total alternations.
Novel object recognition test: Each mouse was first habituated to a black plastic chamber (22 cm wide 9 27 cm long 9 30 cm high) for 7 min, at 24 h intervals. After 2 days of training trial, the mice were presented with two objects and allowed to explore them freely for 7 min. In the testing trial, performed 24 h later, one of the familiar objects was replaced by a novel object and the mice's recognition performance was evaluated for 7 min. Object recognition was defined as the mouse spending time orienting toward the object within a distance of approximately 1 cm, sniffing the object, or touching it with the nose. SH-SY5Y cells were transfected with GFP-microtubule-associated protein light chain 3 (LC3) and incubated with vehicle (Veh), 1 lM rapamycin (Rapa), 1 lM pimozide (Pimo) or 1 lM sulpiride (Sulpi) for 24 h. GFP-LC3 dot formation was examined under confocal microscope (a). The numbers of GFP-LC3 dots per cell were counted from three independent experiments and represented as bars (b, means AE SEM, one-way ANOVA followed by Tukey's post hoc test, **p < 0.05). (c) SH-SY5Y cells were treated with the indicated drug alone or together with 5 lM chloroquine (CQ) for 24 h and cell lysates were analyzed with western blotting (left). The signals on the blots were quantified by densitometric analysis. Bars represent means AE SEM (right, n = 3, two-way ANOVA followed by Bonferroni's post hoc test, *p < 0.05, **p < 0.01, ***p < 0.001). (d and e) HeLa cells were transfected with GFPmCherry-LC3 for 24 h, incubated with 1 lM rapamycin, 1 lM pimozide or 1 lM sulpiride for 24 h, and then observed under confocal microscope (d). Ten cells in each image were randomly selected and the numbers of GFP-LC3 and mCherry dots per cell were counted. Bars represent means AE SEM (E, n = 3, one-way ANOVA followed by Tukey's post hoc test, ***p < 0.001).
Statistical analysis
All experiments were performed at least three times. Statistical analyses were performed using GraphPad Prism software. Results were given as mean AE standard error mean values. Statistical significance of differences was determined by ANOVA, followed by post hoc analysis. p values < 0.05 were considered as statistically significant.
Results
The effect of pimozide on autophagy induction is independent of dopamine D2 inhibition To characterize the effect of pimozide on autophagy in detail, we tested the role of another dopamine D2 receptor antagonist in autophagy and compared the two. As reported earlier (Zhang et al. 2007 ), treatment of SH-SY5Y human neuroblastoma cells with pimozide increased LC3 dot formation as much as rapamycin, a well-known inhibitor of mTOR ( Fig. 1a and b) . On the other hand, treatment with sulpiride, a drug which is also used to treat schizophrenia and inhibits dopamine D2 receptor activity (Pringsheim and Marras 2009) , did not affect LC3-GFP puncta formation. Accordingly, the results from western blot analysis revealed that, unlike rapamycin and pimozide which increased LC3-II conversion and decreased the level of p62, an ubiquitinbinding autophagy receptor, sulpiride did not induce these changes (Fig. 1c) . In addition, LC3-II conversion was further and significantly increased by pimozide treatment in the presence of chloroquine, the lysosomal inhibitor as seen by rapamycin treatment. Together, the results support that pimozide increases autophagy flux. Furthermore, the mCherry-GFP-LC3 assay in which the appearance of mCherry dots indicates the presence of LC3 in autolysosomes, respectively (Pankiv et al. 2007) , showed that the numbers of mCherry dots were increased by treatment with pimozide, but not much by treatment with sulpiride ( Fig. 1d  and e) . We confirmed the expression of dopamine D2 receptor in SH-SY5Y and primary neuronal cells, which was reported previously (Ciliax et al. 1995) , using RT-PCR analysis ( Figure S1 ). These results indicate that pimozide increases autophagy flux independently of dopamine D2 receptor inhibition.
Pimozide activates autophagy through AMPK To find the mechanism by which pimozide regulates autophagy, we explored autophagy signaling pathways. We observed that treatment with pimozide did not affect the phosphorylation of mTOR, S6K, a down-stream substrate of mTOR, and S6 in SH-SY5Y cells, while rapamycin inhibited the phosphorylation of all three (Fig. 2a) . We then tested whether pimozide activated AMPK, which detects low energy levels in cells and negatively regulates mTOR via TSC1/2 phosphorylation (Di Nardo et al. 2014) and/or directly activates ULK for autophagy induction (Kim et al. 2011) . In SH-SY5Y cells, we found that treatment with pimozide increased the phosphorylation of AMPK at the Thr172 residue, an activated form of AMPK (Mihaylova and Shaw 2011) , in a dose-dependent manner (Fig. 2b) . In addition, LC3 dot formation triggered by pimozide was significantly inhibited by co-treatment with compound C (Fig. 2c) , an AMPK inhibitor (Zhou et al. 2001) . Thus, it seems that pimozide activates AMPK to enhance autophagy without affecting mTOR.
Utilizing AMPK1/2 knockout (KO) MEFs, we further evaluated the necessity for AMPK in pimozide-induced autophagy. The results from the mCherry-GFP-LC3 assay revealed that pimozide significantly increased the numbers of mCherry dots in WT MEFs (Fig. 2d) . In AMPK1/2 KO MEFs, in contrast, this increase in autophagic flux was not observed. In addition, we analyzed whether AMPK influenced the activation of ULK1, a Ser/Thr kinase initiating autophagy (Russell et al. 2013) . Western blot analysis showed that treatment with pimozide increased the phosphorylation of ULK1 at Ser555, an activated form of ULK1 (Egan et al. 2011) , in WT MEFs without affecting the total level of ULK1 ( Fig. 2e and f) . However, treatment with pimozide did not affect the phosphorylation of ULK1 in AMPK1/2 KO MEFs. Unlike rapamycin, pimozide increased LC3-II conversion in WT MEFs but not in AMPK KO MEFs. Together, these results suggest that pimozide activates AMPK to induce autophagy through ULK1.
Neuronal aggregation of tau is reduced by pimozide Because the aggregation of abnormally phosphorylated tau is cleared by autophagy processes (Boland et al. 2008) , we decided to test the effect of pimozide on tau pathology. We previously reported that we established a tau aggregation cell-based assay utilizing GFP-tagged tau (Kim et al. 2015) and confirmed that treatment of SH-SY5Y cells with rapamycin reduced the number of cells harboring tau aggregates ( Fig. 3a and b) , consistent with previous results (Bove et al. 2011) . Like rapamycin, treatment with pimozide reduced cellular aggregates of GFP-tau in the same cells. In addition, western blot analysis showed that treatment with rapamycin or pimozide, but not with sulpiride, decreased levels of total tau (TG5) and phosphorylated forms of tau (PHF1 and MC-1) which are frequently found in tau filaments (Gotz et al. 2010) (Fig. 3c) . Similarly, the results from a filter trap assay revealed that the amount of SDSinsoluble tau aggregates was reduced by treatment with rapamycin or pimozide in SH-SY5Y expressing tau (Fig. 3d) . These results suggest that pimozide reduces the aggregates of highly phosphorylated tau.
Dendritic spines are important for synaptic transmission and plasticity (Nimchinsky et al. 2002) . Previous studies showed that tau plays an essential role in the memory impairments that occur in AD model mice expressing Ab precursor protein (APP) (Roberson et al. 2007) , and that (b) SH-SY5Y cells were treated with the indicated concentrations of pimozide for 4 h and the phosphorylation of AMPK and ULK1 was analyzed by western blotting (left). The signals on the blots were quantified and bars indicate mean AE SEM (right, n = 3, one-way ANOVA followed by Tukey's post hoc test, *p < 0.05). (c) SH-SY5Y cells were transfected with GFP-microtubule-associated protein light chain 3 (LC3) for 24 h and incubated with 1 lM pimozide, 1 lM compound C (Comp.C) or both chemicals for 4 h. GFP-LC3 dot formation was examined under confocal microscope (c, upper). The numbers of GFP-LC3 dots per cell were counted and represented as bars with means AE SEM (c, lower, n = 3, one-way ANOVA followed by Tukey's post hoc test, **p < 0.01, ***p < 0.001). (d) AMPK Wild-type (WT) and KO mouse embryo fibroblasts (MEFs) were transfected with mCherry-GFP-LC3, incubated with 1 lM rapamycin or 1 lM pimozide for 24 h. GFP-LC3 was then observed under confocal microscope (d, left). Ten cells in each image were randomly selected and the numbers of GFP-LC3 and mCherry dots per cell were quantified (d, right). Bars represent means AE SEM (n = 3, two-way ANOVA followed by Bonferroni's post hoc test, **p < 0.01, ***p < 0.001). (e and f) AMPK WT and KO MEF cells were incubated the indicated concentrations of rapamycin (e) and pimozide (f) for 24 h. Cell lysates were analyzed with western blotting (upper) . The signals of p-ULK1 and LC3-II on the blots were quantified by densitometric analysis and normalized by ULK1 and b-actin, respectively, (lower, mean AE SEM, n = 3, two-way ANOVA followed by Bonferroni's post hoc test, *p < 0.05, **p < 0.01, ***p < 0.001).
mutant tau is likely to be involved in a significant loss of dendritic spines and synapses (Mocanu et al. 2008; Bittner et al. 2010; Rocher et al. 2010; Kam et al. 2016) . We therefore addressed the role of pimozide in Ab 42 -induced loss of spine density in primary cultured neurons as well. We observed that treatment of mouse hippocampal neurons with oligomeric Ab 42 induced a loss of dendritic spines, and this change in dendritic spine density was significantly ameliorated by treatment with pimozide, but not with sulpiride (Fig. 3e) . In addition, an increase in the levels of both SDSinsoluble tau aggregates (Fig. 3f, upper) , which were triggered by the treatment with oligomeric Ab 42 , was diminished by the treatment with pimozide. The previous studies showed that oligomeric Ab 42 impedes autophagy (Caccamo et al. 2010; Lai and McLaurin 2012; Nilsson et al. 2013) . We also confirmed the inhibitory effect of oligomeric Ab 42 on autophagy at toxic doses. Interestingly, pimozide treatment overcame the autophagy inhibition triggered by oligomeric Ab 42 . (Fig. 3f, lower) . These results suggest that pimozide also plays a role in rescuing the loss of spine density and reduces aggregation of phosphorylated tau in Ab 42 -treated primary neurons. While a report suggested that AMPK regulates GSK3b (Horike et al. 2008; Choi et al. 2010) , here, pimozide did not affect the inhibitory phosphorylation of GSK3b ( Figure S2 ).
Memory deficits in TauC3 AD mice are alleviated by pimozide
These observations led us to analyze the effects of pimozide on the pathogenesis of an AD mouse model. We recently developed a novel AD mouse model which expresses a caspase-cleavage product of tau (TauC3) lacking C-terminal 40 amino acids and exhibits early memory impairments along with the formation of tau oligomers . This form of tau, TauC3, is found in the brain of patients with AD and exhibits neurotoxicity (Chung et al. 2001) . One month-old TauC3 mice were injected with pimozide daily for 30 days and examined for memory impairments (Fig. 4a) . As reported above, the results from a Y-maze test showed that spatial working memory impairment was evident at 2 months in TauC3 mice (69-56%) (Fig. 4b) . On a Y-maze test at 30 days after the first drug injection, spatial memory impairment was remarkably rescued by pimozide in TauC3 mice, almost to the level of controls (Fig. 4b ). In the novel object recognition test, compared to TauC3 mice, TauC3 mice treated with pimozide spent more time exploring the novel object than the object explored 1 day before, illustrating that recognition memory was also improved by pimozide (Fig. 4c) . On both tests, pimozide did not significantly affect memory in age-matched WT mice.
Tau oligomers and aggregates are reduced in TauC3 mice showing enhanced autophagy To assess how pimozide rescues tau pathology in the brain of TauC3 mice, we first investigated autophagy activity in these mice. Western blot analysis revealed that levels of p62 were reduced by treatment with pimozide in the hippocampus of TauC3 mice, while LC3-II levels were increased by treatment with pimozide (Fig. 5a , Figure S3a and b) . We observed more evident regulation of p62 and LC3-II in TauC3 mice than control mice. As seen in neuronal cells, levels of phosphorylated AMPK at Thr172 and ULK1 at Ser555, but not those of total AMPK and ULK1, were apparently increased in the hippocampus of TauC3 mice following treatment with pimozide (Fig. 5b) . Thus, it is likely that pimozide induces autophagy activation through the AMPK-ULK1 axis in the brain of TauC3 mice.
In the same brain samples, western blot analysis revealed that treatment with pimozide reduced the levels of PHF-1 and MC-1-positive tau protein in TauC3 mice (Fig. 5c) . Consistently, immunohistochemical analysis using AT8, an antibody detecting the initiation step of tau phosphorylation in AD (Augustinack et al. 2002) , showed that tau phosphorylation at the AT8 epitope was reduced after treatment with pimozide (Fig. 5d) . To dissect these effects of pimozide on tau phosphorylation in tau pathogenesis, we measured levels of soluble tau oligomers following pimozide treatment. From the western blot analysis using total tau antibody (TG5) Fig. 3 Pimozide reduces aggregation of the phosphorylated tau and recovers spine density in neuronal cells. (a and b) SH-SY5Y cells transfected with GFP-tau were exposed to 1 lM rapamycin, 1 lM pimozide or 1 lM sulpiride for 24 h and then observed under fluorescence microscope. Arrow heads indicated tau aggregation (a).
The numbers of GFP-tau aggregate-positive cells were counted and represented as bars (b, means AE SEM, n > 3, one-way ANOVA followed by Tukey's post hoc test, ***p < 0.001). (c and d) SH-SY5Y cells were transfected with GFP-tau and incubated with 1 lM rapamycin, 1 lM pimozide or 1 lM sulpiride for 24 h. Cell lysates were analyzed by western blotting (c, upper) or filter trap assay. The blots of the filter trap assay were stained with PonceauS or proved by western blotting using tau antibody (d, upper) . Bars represent means AE SEM (c and d, lower, n > 3, one-way ANOVA followed by Tukey's post hoc test, *p < 0.05, **p < 0.01, ***p < 0.001). (e) Mouse hippocampal neurons were transfected with DsRed plasmid and treated with 5 lM Ab 42 alone or together with either 1 lM pimozide or sulpiride for 12 h. Dendritic spines were examined under a fluorescence microscope. Scale bar, 10 lm (upper). The numbers of spine in the image were counted and bars represent means AE SEM (lower, each group; n = 21, ***p < 0.0001). (f) Mouse primary hippocampal neurons were cultured for 15 days in vitro (DIV-15) and exposed to 5 lM Ab 42 in the absence or presence of either 1 lM pimozide or sulpiride for 16 h. Cell extracts were analyzed by filter trap assay (upper) or western blotting (WCL) (lower) (left). Bars represent means AE SEM (right, n = 3, oneway ANOVA followed by Tukey's post hoc test, *p < 0.05, **p < 0.01, ***p < 0.001).
under non-reducing condition, we could detect both tau monomers (~50 kDa) and oligomers (~170 kDa) in the brain of TauC3 mice. Of particular note is that levels of tau oligomers, which were detected only in the brain of TauC3 mice showing memory deficits , were apparently reduced by treatment with pimozide in TauC3 mice (Fig. 5e ). In the same blots, we confirmed that tau oligomers were TauC3-positive human TauC3 and T22-positive tau oligomers (Fig. 5e) . These results indicate that pimozide reduces levels of soluble tau oligomers in the hippocampus of TauC3 mice.
Using fractionation assays, we further separated the hippocampal extracts into NP-40-insoluble (70% FA-soluble) tau (TG5) and NP-40 (RIPA)-soluble PHF-1 tau. Western blot analysis of the fractions indicated that treatment with pimozide markedly reduced the amounts of both NP-40-soluble PHF-1 tau (RIPA) and NP-40-insoluble (70% FAsoluble) tau (TG5) (Fig. 5f ). Similarly, a filter trap assay revealed that SDS-resistant insoluble tau aggregates which were highly detected in TauC3 mice was diminished by treatment with pimozide (Fig. 5g) . Tau protein in these aggregates was highly phosphorylated (PHF-1) and included most of human TauC3 (HT7). Together, these results illustrate that pimozide has a function in memory improvement in TauC3 mice by reducing phosphorylated tau oligomers and aggregates, probably through enhancing autophagy.
Discussion
The activities of protein quality control systems, such as autophagy and the ubiquitin-proteasome system, are declining with age, leading to an increase in the amount of misfolded or aggregated proteins (Nixon 2013; Vilchez et al. 2014) . Especially the accumulation of abnormally modified tau (oligomeric and pro-fibril forms) has been considered a major pathogenic factor for the neurodegeneration in AD and other tauopathies (Wegmann et al. 2015) . More recent studies have shown that detergent-insoluble, high-n tau filamentous aggregates play pivotal roles in tau neurotoxicity as major transmittable sources (Stancu et al. 2015) . It is thus a striking finding that pimozide efficiently eliminates NP-40 or SDS-insoluble tau aggregates as well as soluble tau oligomers in TauC3 mice. Interestingly we found that level of soluble tau oligomers in TauC3 mice was also reduced by pimozide. Though we cannot exclude a possibility that pimozide eliminates tau oligomer, we believe that the ability of pimozide to eliminate insoluble tau affects level of tau oligomer. Autophagy usually functions by removing insoluble protein aggregates. Based on previous data suggesting that pimozide plays a crucial role as an autophagy activator (Zhang et al. 2007) , we explored the correlation between pimozide-mediated autophagy regulation and tau toxicity. Therefore, this research provides insights into the possibility that degradation and clearance of pathogenic species of tau by enhancing activities of autophagy could prevent or treat the disease.
In this study, we found that pimozide regulates autophagic flux by activating ULK1 through AMPK in a mTORindependent manner. Previous studies showed that AMPK regulates autophagy through two different pathways; it inhibits mTOR by affecting upstream TSC1/2 (Di Nardo et al. 2014) and also directly phosphorylates ULK1 at Ser 555 for activation (Bach et al. 2011) . Although pimozide stimulates autophagy via the AMPK-ULK1 signaling axis, there are Wild-type (WT) and TauC3 mice were daily i.p.-injected from 1 month of age for 30 days with phosphate-buffered saline (PBS) or pimozide (10 mg/kg) (a). Spatial memory was measured twice with Y-maze test at 1.3 months (10 days after injection) and 2 months (30 days after injection) of age (b). Recognition memory was examined with novel object recognition test at 2 months of age (c). Data are means AE SEM (n = WT PBS, four males and six females; WT pimozide, five males and five females; TauC3 PBS, eight males and six females; TauC3 pimozide, eight males and five females, **p < 0.05, ***p < 0.005).
Fig. 5
Pimozide enhances autophagy and reduces levels of tau oligomers and aggregates in TauC3 mouse brain. (a) Wild-type (WT) and TauC3 mice were daily i.p.-injected with phosphate-buffered saline (PBS) or pimozide (10 mg/kg) from 5 weeks of age for 3 weeks. The hippocampal tissues were analyzed with western blotting (upper) . The signals on the blots were quantified by densitometric analysis and normalized by tubulin (lower, mean AE SEM, n > 3, two-way ANOVA followed by Bonferroni's post hoc test, *p < 0.05, **p < 0.01). (b) The hippocampal tissues of WT and TauC3 mice examined in Fig. 4 were analyzed with western blotting for AMPK signaling (left). Signals on the blots were quantified with densitometric analysis (right). Bars denote means AE SEM (n = 3, two-way ANOVA followed by Bonferroni's post hoc test, *p < 0.05). (c) The hippocampal tissues examined in (b) were analyzed with western blotting (left). Bars denote means AE SEM (right, n = 3, two-way ANOVA followed by Bonferroni's post hoc test, *p < 0.05). (d) The CA3 regions in the hippocampus of WT and TauC3 mice were analyzed with immunohistochemistry. Scale bars, 100 lm. (e-g) The hippocampal tissue extracts examined in (b) were separated by PAGE under non-reducing condition and analyzed with western blotting. Arrows: tau oligomers, arrowhead: tau monomer (e). Detergent-insoluble tissue extracts [radioimmunoprecipitation assay buffer (RIPA)-insoluble (FA-soluble) fractions] were separated and subjected to western blotting (f) or filter-trap assay (g). Bars denote means AE SEM (n = 3, two-way ANOVA followed by Bonferroni's post hoc test, *p < 0.05, **p < 0.01, ***p < 0.001).
still missing links between pimozide and AMPK. We first hypothesized that pimozide might regulate autophagy activity as a dopamine D2 antagonist. The dopamine D2 receptor is known to regulate the MAPK signaling pathway which is involved in autophagy and proteasomal degradation (RangelBarajas et al. 2015) . However, down-regulation of dopaminergic receptor activity using sulpiride, a well-known drug for anti-psychosis treatment, as in schizophrenia and major depressive disorder, altered neither tau aggregation nor autophagy activity in neuronal cells. According to results suggesting that sulpiride is a more selective inhibitor for dopamine D2 receptor compared to pimozide, these effects of pimozide on autophagy and tau aggregation are not likely because of its function as a dopamine D2 antagonist.
Cytosolic Ca 2+ levels have been reported to have a dual function in autophagy activation and inhibition. Previously it was shown that the increase in cellular Ca 2+ can stimulate CAMKKb, which then activates AMPK, leading to inhibition of mTOR (Grotemeier et al. 2010) . Although pimozide functions as a blocker of Ca 2+ channel (Enyeart et al. 1990 ), however, we observed that it activates autophagy via AMPK. In addition, we observed that treatment with thapsigargin, an ER Ca 2+ channel blocker, affected autophagy activity and tau aggregation in pimozide-treated neuronal cells (data not shown), and that pimozide evoked autophagy activation independently of mTOR. We also could not observe any cleavage of Atg5, which is mediated by Ca 2+ -activated calpain (Xia et al. 2010) . To summarize, it seems that pimozidemediated AMPK activation is not related to CAMKKb. Recently, many studies about pimozide are being reported; an inhibitor of STAT3 (Chen et al. 2015) , STAT5 (Nelson et al. 2011) , and FABP4, a protein that regulates activity of PPARc (peroxisome proliferator-activated receptor gamma) (Wang et al. 2015) . Thus, the question of how pimozide regulates AMPK for the stimulation of autophagy remains open and needs to be further addressed.
In conclusion, we propose that pimozide enhances autophagy activity by stimulating the AMPK-ULK1 axis to reduce toxic forms of tau protein and can thus be considered a therapeutic compound to manipulate tau-mediated neuropathology in AD and other tauopathies. 2N42750-17-068) funded by the Ministry of Education, Science and Technology. The authors declare no conflict of interest.
All experiments were conducted in compliance with the ARRIVE guidelines.
Supporting information
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